Pancreatic Cancer clinical trials in Georgia

28 actively recruiting pancreatic cancer trials at 14 sites across Georgia.

Data from ClinicalTrials.gov · last refreshed 2026-07-27

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

RayzeBio, Inc. funds and runs this clinical trial (NCT05477576). In 2024, RayzeBio, Inc. reported paying the doctors leading the trial a total of $4,828,235 for research work on this study.

Who paid

E.R. Squibb & Sons, L.L.C. $4,828,235

Paid for research work on this trial

THORVARDUR HALFDANARSON(oncologist on CancerDrs) $748,451
MICHAEL MORRIS $460,348
JONATHAN STROSBERG(oncologist on CancerDrs) $398,373
ARVIND DASARI(oncologist on CancerDrs) $348,401
DANIEL HALPERIN(oncologist on CancerDrs) $348,401

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Eli Lilly and Company funds and runs this clinical trial (NCT06586515). In 2024, Eli Lilly and Company reported paying the doctors leading the trial a total of $64,600 for research work on this study.

Who paid

Eli Lilly and Company $64,600

Paid for research work on this trial

CESAR BATISTA(oncologist on CancerDrs) $32,250
VIVEK SUBBIAH(oncologist on CancerDrs) $19,250
NATRAJ AMMAKKANAVAR(oncologist on CancerDrs) $13,100

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT06998940

Sites in Georgia:

Emory University Hospital Midtown — Atlanta, Georgia
Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Emory Saint Joseph's Hospital — Atlanta, Georgia
Emory Decatur Hospital — Decatur, Georgia
Emory Johns Creek Hospital — Johns Creek, Georgia